Daniel Morgensztern

14PUBLICATIONS
129CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Apr 30, 2026
Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.

|Jan 22, 2026
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.

Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki

|Oct 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.

Melissa L Johnson, Egbert F Smit, Enriqueta Felip

|Jul 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.

Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki

|Jun 30, 2025
Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer.

Rotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez

|May 07, 2025
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.

Di Kang, Yanping Wang, Yiwei Lin

Pageof 3

Frequent Collaborators

4 joint publications

Enriqueta Felip

4 joint publications

Ramaswamy Govindan

3 joint publications

Melissa L Johnson

3 joint publications

Jonathan W Goldman